Novo Nordisk A/S purchases B shares worth DKK 1,038 million from Novo Holdings A/S under the 2018 share repurchase programme

Bagsværk, Denmark, 4 May 2018 – Novo Nordisk A/S has today entered into an agreement to purchase 3,415,895 B shares (nominal DKK 0.20) of a value of DKK 1,038 million from Novo Holdings A/S. This transaction is part of Novo Nordisk’s 2018 share repurchase programme of up to a total of DKK 14.0 billion to be executed during a 12 months period beginning 1 February 2018. The transaction price is DKK 303.83 per share and has been calculated as the volume weighted average market price from 2 May to 4 May 2018 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results.

Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.2% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 157,310,695 B shares of DKK 0.20, corresponding to 28.4% of the capital and 76.2% of the votes in Novo Nordisk A/S.

The transaction is in line with the announcement on 2 May 2018 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.

Transactions related to Novo Nordisk A/S’ incentive programmes have resulted in a net transfer from Novo Nordisk of 3,155 B shares of DKK 0.20 in the period from 2 May 2018 to 4 May 2018. Novo Nordisk A/S owns a total of 24,743,093 B shares of DKK 0.20, corresponding to 1.0% of the share capital, as treasury shares including this transaction. The total amount of A and B shares in the company is 2,450,000,000 of DKK 0.20 including treasury shares.
About Novo Holdings A/S

Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundation’s assets.

In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets.

It is the vision of Novo Holdings to be recognized as a world-leading life science investor with a focus on creating long-term value. Read more at www.novo-holdings.dk.

About Novo Nordisk A/S

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Nov-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Novo Holdings Communication
Christian Mostrup Scheel +45 3067 4805 cims@novo.dk

Novo Nordisk Media:
Katrine Sperling +45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

Novo Nordisk Investors:
Peter Hugreff Ankersen +45 3075 9085 phak@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Christina Kjær +45 3079 3009 cnje@novonordisk.com